transmembrane protein 167BGenealiases: AD-020 · C1orf119
Q-omics provides the consensus-scored TMEM167B profile across patient tissues and cancer cell-line models. TMEM167B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, TMEM167B is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, TMEM167B RNA expression shows 19,726 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight SCLC, THCA, and ACC as cancer lineages where TMEM167B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM167B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM167B survival associations across molecular data types. TMEM167B RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM167B RNA expression–survival associations across cancer types. High TMEM167B expression shows unfavorable associations in SCLC, KICH, ACC, LIHC and LGG, but favorable associations in KIRC. The SCLC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify SCLC as the clearest survival context for TMEM167B RNA expression.
This table summarizes TMEM167B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TMEM167B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM167B shows lower tumor expression in THCA, KICH, COAD and LUAD and higher tumor expression in LIHC and HNSC. The THCA box plot shows higher TMEM167B RNA expression in normal versus tumor tissue (log2 FC = −1.001, t-test p < 0.001).
This table shows molecular features associated with TMEM167B in patient tissues and cancer cell lines. In patient samples, TMEM167B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM167B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
